D’Amico and coworkers in 1998 developed a classification system of prostate cancer based on clinical parameters (PSA, Gleason score and clinical staging) to group these patients into low-, intermediate-, and high-risk of relapse after therapy with curative intent [326]. This evidence concerns the gene KLK3 and prostate cancer.